OARSI update on the evidence for osteoarthritis therapies: comment on the nomenclature used for intra-articular hyaluronan  by Band, P.A.
Osteoarthritis and Cartilage 18 (2010) 1235Letter to the Editor
OARSI update on the evidence for osteoarthritis therapies: comment on the
nomenclature used for intra-articular hyaluronanPlease allow me to clarify the terminology used to describe
the intra-articular hyaluronan (IAHA) class of osteoarthritis
(OA) treatments, in the excellent evidence update reported by
Zhang et al. (OARSI recommendations for the management of
hip and knee osteoarthritis part III: changes in evidence
following systematic cumulative update of research published
through January 2009. Osteoarthritis and Cartilage, February 17,
2010; 18(4); 473–99).
In Table IV, the authors report a lower risk of local reactions for
“IAHA” compared to “IA high molecular HA (hylan)”. This incor-
rectly suggests that the risk reported from the hylan G-F 20 trials
is representative of all high molecular weight HA formulations.
This is not the case, as HA and hylan are chemically distinct entities.
Hylan is a generic term used to describe a class of HA derivatives
chemically modiﬁed via their hydroxyl groups1. The hylan formula-
tion tested in the reviewed trials, hylan G-F 20, contains both hylan
A, a soluble high molecular weight derivative of HA, and hylan B,
a crosslinked HA derivative that is a water insoluble hydrogel.
This distinction between hylan and high molecular weight HA
formulations is important, to avoid suggesting that the clinical
proﬁle described for hylan G-F 20 applies in a general way to all
high molecular weight HA formulations.
It is also worthwhile to note that all HA derivatives should not
be expected to have the same clinical proﬁle as hylan G-F 20. HA
derivatives can be synthesized using different chemical methods,
and formulated as different physical forms (e.g., solutions, solid
hydrogels or gel–ﬂuid mixtures). The safety and effectiveness of1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2010.03.019each derivative formulation should be evaluated for its intended
use.
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